gemcitabine + cisplatin + PD-1 antibody

This combination therapy regimen consists of the antimetabolite gemcitabine, the platinum-based alkylating agent cisplatin, and a monoclonal antibody targeting the Programmed Cell Death Protein 1 (PD-1) receptor. This triplet regimen has become a standard of care for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). Gemcitabine and cisplatin provide cytotoxic debulking and potentially increase tumor immunogenicity, while the PD-1 antibody blocks the PD-1/PD-L1 pathway to restore T-cell mediated anti-tumor immune responses. Sun Yat-sen University has been a leading institution in clinical trials establishing this regimen's efficacy, often evaluating it as a backbone for novel therapeutic additions such as EBV lytic reactivation therapy.

Other names

Gemcitabine-Cisplatin-PD-1Gemcitabine-Cisplatin-PD1Gemcitabine-Cisplatin-PD 1GP plus PD-1 inhibitorGP plus PD-1 antibody